Navigation Links
Accurate Identification of Tumor Origin Using MicroRNAs is Published by Rosetta Genomics' Scientists and Collaborators in Nature Biotechnology
Date:3/24/2008

aterially from those indicated by these forward-looking statements as a result of various important factors, including risks related to: Rosetta's approach to discover and develop novel diagnostics and therapeutic tools, which is unproven and may never lead to marketable products or services; Rosetta's ability to fund and the results of further pre-clinical and clinical trials; Rosetta's ability to obtain, maintain and protect the intellectual property utilized by Rosetta's products; Rosetta's ability to enforce its patents against infringers and to defend its patent portfolio against challenges from third parties; Rosetta's ability to obtain additional funding to support its business activities; Rosetta's dependence on third parties for development, manufacture, marketing, sales, and distribution of products; Rosetta's ability to successfully develop its candidate tools, products and services, all of which are in early stages of development; Rosetta's ability to obtain regulatory clearances or approvals that may be required for its products and services; the ability to obtain coverage and adequate payment from health insurers for the products and services comprising Rosetta's technology; competition from others using technology similar to Rosetta's and others developing products for similar uses; Rosetta's dependence on collaborators; and Rosetta's short operating history; as well as those risks more fully discussed in the "Risk Factors" section of Rosetta's Annual Report on Form 20-F for the year ended December 31, 2006 as filed with the Securities and Exchange Commission. In addition, any forward-looking statements represent Rosetta's views only as of the date of this release and should not be relied upon as representing its views as of any subsequent date. Rosetta does not assume any obligation to update any forward-looking statements unless required by law.

Contact: Media

Rachel Spielman

T: +1-212-583-2714

E:

SOURCE Rosetta Genomics Ltd
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. CryoLife Responds to Inaccurate Assertions from Plaintiffs Attorney
2. ABCs Private Practice Inaccurately Portrays Serious Womens Health Condition
3. Mobidiag Releases First Microarray Based Rapid Test for Herpesvirus Identification
4. Anavex 7-1037 reduces rate of cancer tumor growth 69% in pre-clinical studies, compared to currently marketed drug Dacarbazine showing no measurable activity
5. Publication in Clinical Cancer Research Confirms Ability of Peregrines Bavituximab to Target Tumor Blood Vessels with Excellent Specificity
6. EntreMed Presents Interim Results for Phase 2 Carcinoid Tumor Study
7. Brostallicin Trial Data Demonstrates Encouraging Anti-tumor Activity in Patients With Chemotherapy-Resistant Cancers
8. Virginia Commonwealth University to Study Genomics-Based Diagnostic Test: Pathwork Diagnostics Tissue of Origin Test Designed to Aid in Determination of a Tumors Origin
9. On the road to a new cancer therapy -- starving the tumor
10. Elekta Announces Elekta Infinity - a New System for Faster and More Precise Treatment of Cancer Tumors
11. Celator(R) Pharmaceuticals Study Shows CPX-571 Maintains Synergistic Ratio of Irinotecan and Cisplatin to Improve Anti-tumor Activity
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/29/2014)... emerging diseases and biodiversity loss requires evolutionary thinking, ... Science Express that was co-authored by Bruce ... Agriculture and Life Sciences. , For the first ... reviewed progress in addressing a broad set of ... approaches that consider evolutionary histories and the likelihood ...
(Date:9/29/2014)... Albany,NY (PRWEB) September 29, 2014 Transparency ... (by Synthesis - SPPS, LPPS, HPPS, by Application - ... Innovative & Generic and by Delivery) - Global Industry ... 2018’, states that the global peptide therapeutics market was ... reach US$25.4 billion by 2018 at an 8.7% CAGR. ...
(Date:9/29/2014)... SQI Diagnostics Inc. (TSX-V: SQD) (OTCQX: SQIDF), a life ... products for advanced microarray diagnostics, is pleased to announce ... of the Board of Directors of SQI, replacing ... as a Director on the Board and will continue ... "We are very pleased to have Mr. Winkley assume ...
(Date:9/29/2014)... ZIONA, Israel , September 29, ... stage company developing novel immunomodulators for severe infections, today ... ( BARDA ) has awarded Atox Bio with a ... for the development of AB103 to treat Necrotizing Soft ... and public health threats that end in sepsis. ...
Breaking Biology Technology:Evolutionary biology: It's not just for textbooks anymore 2Evolutionary biology: It's not just for textbooks anymore 3Global Peptide Therapeutics Market to be Worth US$25.4 Billion by 2018: Transparency Market Research 2Global Peptide Therapeutics Market to be Worth US$25.4 Billion by 2018: Transparency Market Research 3SQI Diagnostics Announces New Chairman of Board of Directors 2Atox Bio Awarded Contract Worth up to $24 Million for the Development of AB103 by the Biomedical Advanced Research and Development Authority (BARDA) 2
... Educational program offers unique resources to empower transplant patients ... ... Oct. 17 Astellas Pharma US,Inc. (Pink Sheets: ALPMF), a ... Society (ITNS), a leading transplant,professional organization, announced a collaborative partnership ...
... to Dominate the Type 2 Diabetes Market, According to a ... New Report from Decision Resources, ... have released a new report finding that Merck,will obtain blockbuster antidiabetic ... uptake of their DPP-IV inhibitor, Januvia.,Januvia will see rapid uptake as ...
... 24, at 1:30 p.m. EDT, ALAMEDA, Calif., ... a biopharmaceutical company developing innovative therapies,for the treatment ... to discuss third quarter results on Wednesday, October ... Kenneth Chahine, Chief Executive,Officer, and Michael Coffee, Chief ...
Cached Biology Technology:Astellas Pharma US, Inc. and The International Transplant Nurses Society (ITNS) Collaborate on Content for Transplant Experience Program 2Astellas Pharma US, Inc. and The International Transplant Nurses Society (ITNS) Collaborate on Content for Transplant Experience Program 3Merck Will Obtain Blockbuster Antidiabetic Drug Sales in Type 2 Diabetes Market by 2011 2Merck Will Obtain Blockbuster Antidiabetic Drug Sales in Type 2 Diabetes Market by 2011 3Avigen, Inc. Announces Third Quarter 2007 Earnings Conference Call 2
(Date:9/29/2014)... annual Advocacy Awards will ... advancing medical progress to improve the health and ... take place on Wednesday, March 11, 2015, at ... , The 2015 Advocacy Award winners are ABC,s ... founder of the Milken Institute and FasterCures; Dr. ...
(Date:9/29/2014)... beginning of the age of dinosaurs, gigantic reptilesdistant relatives ... and others in water and it was thought they ... University of Tennessee, Knoxville, researcher in the thigh of ... , Stephanie Drumheller, an earth and planetary sciences ... Sterling Nesbitt examined 220-million-year-old bite marks in the thigh ...
(Date:9/29/2014)... Institute (DOE JGI), a DOE Office of Science ... have been selected for the 2015 Community Science ... waters, and from plant root micro-ecosystems, to the ... the CSP 2015 projects portfolio highlights diverse environments ... , "These projects catalyze JGI,s strategic shift in ...
Breaking Biology News(10 mins):Research!America to honor leaders in medical and health research advocacy 2Research!America to honor leaders in medical and health research advocacy 3Research!America to honor leaders in medical and health research advocacy 4Tooth serves as evidence of 220 million-year-old attack 22015 DOE JGI's science portfolio delves deeper into the Earth's data mine 22015 DOE JGI's science portfolio delves deeper into the Earth's data mine 32015 DOE JGI's science portfolio delves deeper into the Earth's data mine 42015 DOE JGI's science portfolio delves deeper into the Earth's data mine 52015 DOE JGI's science portfolio delves deeper into the Earth's data mine 62015 DOE JGI's science portfolio delves deeper into the Earth's data mine 72015 DOE JGI's science portfolio delves deeper into the Earth's data mine 82015 DOE JGI's science portfolio delves deeper into the Earth's data mine 9
... neighbors, and now researchers reporting in the June 22 issue ... they have a motive. It appears that chimps, and especially ... gain territory. "The take-home is clear and simple," ... each other. They kill their neighbors. Up until now, we ...
... which aims to develop a new, higher-yielding rice plant which could ... by an academic at the University of Sheffield. Currently, more ... a day and nearly one billion live in hunger. Over the ... about 50 per cent and water scarcity will grow. About half ...
... international public-private consortium to build the most detailed map ... of three pilot projects and the deposition of the ... use by the research community. In addition, work has ... database containing information from the genomes of 2,500 people ...
Cached Biology News:Why chimpanzees attack and kill each other 2Rice yields researched to tackle food security issues 2Rice yields researched to tackle food security issues 3Freely available data supporting next generation of human genetic research 2Freely available data supporting next generation of human genetic research 3Freely available data supporting next generation of human genetic research 4Freely available data supporting next generation of human genetic research 5Freely available data supporting next generation of human genetic research 6
Anti-Potassium Channel EAG-1 Immunogen: Synthetic peptide from the C-terminus of rat Kv10.1 (Accession Q63472). The immunogen sequence is identical in mouse and 14/16 residues identical in human...
WIF-1 (N-20)...
VEGF Receptor-2, phospho-specific (Tyr996)...
For the differentiation of mouse embryonic stem cells tooligodendrocytes....
Biology Products: